Amgen Inc.

AMGN

Held by 5 specialist biotech funds

High Convergence

5 funds opened new positions. Next phase3 readout (Darbepoetin alfa): Nov 2000. Short interest: 2.6% of float.

Drug Manufacturers - GeneralCEO: Robert A. BradwayIPO: 1983Website ↗

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Catalysts

Phase 3PositiveQ4 2000Darbepoetin alfaAnemiaNCT03776032

Primary: Percentage of Participants with a Red Blood Cell Transfusion During Weeks 5 to 12 (Weeks 5 to 12)Enrollment:320/320RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2000CinacalcetPrimary HyperparathyroidismNCT03776058

Primary: Number of Participants with Adverse Events (4 weeks)Enrollment:10/10RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ2 2002EtanerceptJuvenile Rheumatoid ArthritisNCT03781375

Primary: Percentage of Participants With a JRA Response at Month 6 (Baseline and month 6)Enrollment:25/25RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2003darbepoetin alfaAnemia, Non-Myeloid MalignanciesNCT00540696

Primary: Proportion of subjects whose baseline score on the subjective FCST correctly estimates the baseline MHST score (baseline)Enrollment:Target 300RANDOMIZED, TREATMENT

Phase 2PositiveQ3 2003AMG 073Renal OsteodystrophyNCT00527085

Primary: To evaluate the effects of AMG 073 compared with placebo on renal osteodystrophy as assessed by bone histomorphometry (entire study)Enrollment:Target 45RANDOMIZED, TRIPLE, TREATMENT

Phase 2PositiveQ3 2004RomiplostimThrombocytopenic PurpuraNCT00117143

Primary: Number of Participants With Adverse Events (From first dose through 8 weeks after last dose of study drug (11 weeks))Enrollment:16/16NA, TREATMENT

Phase 2NegativeQ4 2004ABX-EGFNon-small Cell Lung Cancer, Neoplasm Metastasis, Lung CancerNCT00101920

Primary: Objective Tumor Response (End of initial 6 week treatment period)Enrollment:50/50NON_RANDOMIZED, TREATMENT

Phase 2Q1 2005Intra-articular metHuIL-1ra (anakinra)OsteoarthritisNCT00110916

Primary: WOMAC (12 weeks)Enrollment:Target 165RANDOMIZED, DOUBLE, TREATMENT

Phase 3PositiveQ1 2006EtanerceptPsoriasisNCT00078819

Primary: Percentage of Participants Achieving a ≥ 75% Improvement in Psoriasis Area and Severity Index Score (PASI 75) at Week 12 (Baseline and week 12)Enrollment:211/211RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 200650 mg EtanerceptRheumatoid ArthritisNCT00249041

Primary: Rates of anti-etanercept antibody formation to etanercept liquid with or without concomitant methotrexate (MTX) therapy at week 24 (24 weeks)Enrollment:447/447NA, TREATMENT

Phase 3NegativeQ1 2007Small Cell Lung CancerNCT00119613

Primary: Change in hemoglobin concentration from baseline to the end of the chemotherapy treatment period (from baseline to the end of the chemotherapy treatment period)Enrollment:Target 600RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ2 2007100 mg AMG 162OsteoporosisNCT00306189

Primary: Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12 (12 months)Enrollment:212/212RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q3 2007EtanerceptRheumatoid ArthritisNCT00413452

Primary: Etanercept seroreactivity response (ie, development of anti-etanercept antibodies) to etanercept (manufactured using the SFP) (24 weeks)Enrollment:224/224NON_RANDOMIZED, TREATMENT

Phase 2PositiveQ2 2008DenosumabGCT, Giant Cell Tumor of BoneNCT00396279

Primary: Percentage of Participants With Giant Cell Tumor Response (From enrollment until 25 weeks)Enrollment:37/37NA, TREATMENT

Phase 2PositiveQ2 2008RomiplostimThrombocytopenia, MDS, Myelodysplastic SyndromesNCT00303472

Primary: Part A: Number of Participants With Adverse Events (Treatment period (4 weeks) plus treatment extension (1 year))Enrollment:72/72NON_RANDOMIZED, TREATMENT

Phase 3ApprovedQ3 2008HZT-501Peptic UlcerNCT00450658

Primary: Number of Subjects Who Develop Endoscopically-diagnosed Upper Gastrointestinal Ulcers Confirmed by Endoscopy. (24 weeks)Enrollment:627/627RANDOMIZED, QUADRUPLE, PREVENTION

Phase 3PositiveQ4 2008Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)NCT00415532

Primary: Number of Participants With Splenectomy During 52-Week Treatment Period (52 weeks)Enrollment:234/234RANDOMIZED, TREATMENT

Phase 3NegativeQ1 2009Kidney Disease, Diabetes Mellitus, AnemiaNCT00093015

Primary: Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia, Congestive Heart Failure (CHF), Myocardial Infarction (MI), and Cerebrovascular Accident (CVA) (Until a primary cardiovascular event (death, myocardial ischemia, congestive heart failure, myocardial infarction or cerebrovascular accident) occurred or 28 March 2009, whichever occurred first)Enrollment:4,038/4,038RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ1 2009PlaceboIdiopathic Thrombocytopenic Purpura, Thrombocytopenia in Pediatric Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP), Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)NCT00515203

Primary: Adverse Events (12 weeks)Enrollment:22/22RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ2 2009MR prednisoneRheumatoid ArthritisNCT00650078

Primary: ACR 20 Response Rate at Visit 4 (Week 12)Enrollment:350/350Sites: 52RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2009alendronateOsteoporosisNCT00518531

Primary: Adherence With Treatment in the First Treatment Period (Treatment period 1 (Month 1 to Month 12))Enrollment:250/250RANDOMIZED, TREATMENT

Phase 2PositiveQ2 2009MP-376Cystic Fibrosis (CF)NCT00677365

Primary: Change in P. Aeruginosa Density (from baseline to end of treatment (28 days))Enrollment:151/151Sites: 50RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2009DenosumabBone MetastasesNCT00321464

Primary: Time to First On-Study Skeletal Related Event (SRE) (Non-inferiority) (Up to 34 months)Enrollment:2,049/2,049RANDOMIZED, TRIPLE, SUPPORTIVE_CARE

Phase 2Q4 2009MDS, Myelodysplastic Syndromes, ThrombocytopeniaNCT00321711

Primary: Occurrence of a Clinically Significant Thrombocytopenic Event (Treatment period (up to 20 weeks))Enrollment:69/69RANDOMIZED, DOUBLE, SUPPORTIVE_CARE

Phase 2PositiveQ1 2011Low Bone Mineral Density, Postmenopausal OsteoporosisNCT00896532

Primary: Percent Change From Baseline at Month 12 in BMD at the Lumbar Spine (Baseline to 12 months)Enrollment:419/419RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2011EtanerceptPediatric Plaque PsoriasisNCT00141921

Primary: Number of Participants With Adverse Events (264 Weeks)Enrollment:182/182NA, TREATMENT

Phase 2PositiveQ1 2012BlinatumomabB-ALLNCT01209286

Primary: Percentage of Participants With a Best Response of Complete Remission or Complete Remission With Only Partial Hematological Recovery Within 2 Cycles of Treatment (Within the first 2 cycles of treatment, 12 weeks)Enrollment:36/36Sites: 9NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2012CinacalcetSecondary Hyperparathyroidism, Chronic Kidney DiseaseNCT00345839

Primary: Time to Primary Composite Endpoint (All-cause Mortality, Myocardial Infarction, Hospitalization for Unstable Angina, Heart Failure or Peripheral Vascular Event) (From date of randomization until date of first confirmed primary composite endpoint event, assessed up to 5.4 years)Enrollment:3,883/3,883RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2012darbepoetin alfaAnemia, Chronic Kidney DiseaseNCT00925587

Primary: Hb Change Between Baseline and the Evaluation Period (Average of Weeks 29-33) (Baseline Week 33)Enrollment:358/358Sites: 157RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2012CisplatinMetastatic or Recurrent Squamous Cell Carcinoma of Head and NeckNCT00454779

Phase 3PositiveQ3 2012Apremilast 20mgPsoriatic ArthritisNCT01212757

Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 (Baseline and Week 16)Enrollment:488/488Sites: 98RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2012CinacalcetChronic Allograft Nephropathy, Chronic Kidney Disease, Chronic Renal FailureNCT00975000

Primary: Percentage of Participants With a Mean Corrected Total Serum Calcium Value < 10.2 mg/dL (2.55 mmol/L) During the Efficacy Assessment Phase (EAP) (Weeks 21 to 26 (EAP))Enrollment:114/114Sites: 51RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ4 2012MP-376 (Levofloxacin Solution for Inhalation)Cystic FibrosisNCT01270347

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) (From start of study until end of the study (up to 168 days))Enrollment:282/282Sites: 130RANDOMIZED, TREATMENT

Phase 2PositiveQ4 2012CarfilzomibMultiple Myeloma, Renal InsufficiencyNCT00721734

Primary: Clearance (CL) of Carfilzomib on Day 1 of Cycle 1 (Cycle 1, Day 1 before dosing, at the end of the injection, 5, 15, 30, and 60 minutes, and 1.5, 2, 4, 6 and 24 hours postdose.)Enrollment:50/50Sites: 5NA, TREATMENT

Phase 3Q1 2013CetuximabMetastatic Colorectal CancerNCT01001377

Primary: Overall Survival (From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.)Enrollment:1,010/1,010Sites: 152RANDOMIZED, TREATMENT

Phase 2PositiveQ2 2013EvolocumabHypercholesterolemia and High Risk for Cardiovascular EventsNCT01652703

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12 (Baseline and Week 12)Enrollment:310/310Sites: 42RANDOMIZED, TRIPLE, TREATMENT

Phase 2NegativeQ2 2013AMG 747SchizophreniaNCT01568216

Primary: Change from baseline to week 12 in negative symptoms, as measured by the NSA-16 total score (12 Weeks)Enrollment:121/121Sites: 38RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2014EtelcalcetideHyperparathyroidism, SecondaryNCT01788046

Primary: Percentage of Participants With > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).)Enrollment:515/515Sites: 106RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ2 2014EtelcalcetideHyperparathyroidism, SecondaryNCT01785849

Primary: Percentage of Participants With a > 30% Decrease From Baseline in Mean PTH During the Efficacy Assessment Phase (Baseline and the efficacy assessment phase (EAP; defined as Weeks 20 to 27, inclusive).)Enrollment:508/508Sites: 118RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ3 2014ApremilastPsoriasis, Psoriatic ArthritisNCT01690299

Primary: Percentage of Participants Who Achieved a 75% Improvement (Response) in the Psoriasis Area Severity Index (PASI-75) for the Comparison Between Apremilast and Placebo at Week 16 From Baseline (Baseline to Week 16)Enrollment:250/250Sites: 82RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ3 2014CarfilzomibMultiple MyelomaNCT01302392

Primary: Overall Survival (From randomization through the final analysis data cutoff with longest follow-up time of approximately 45 months. Median follow up times were 27.8 months and 29.8 months for Carfilzomib and Best Supportive Care groups, respectively.)Enrollment:315/315Sites: 68RANDOMIZED, TREATMENT

Phase 2Q3 2014Diabetic Nephropathy, Type 2 Diabetes MellitusNCT01447147

Phase 3PositiveQ4 2014ABP 501Arthritis, RheumatoidNCT01970475

Primary: Percentage of Participants With an American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24)Enrollment:526/526Sites: 11RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ4 2015BlinatumomabRelapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaNCT02013167

Primary: Overall Survival (From randomization until the data cut-off date of 04 January 2016; median observation time was 11.8 months in the SOC group and 11.7 months in the blinatumomab group.)Enrollment:405/405Sites: 117RANDOMIZED, TREATMENT

Phase 2PositiveQ1 2016Talimogene laherparepvecMelanomaNCT02014441

Phase 3NegativeQ1 2016AMG 386Fallopian Tube Cancer, Ovarian Cancer, Peritoneal CancerNCT01493505

Primary: Progression free survival (3 years)Enrollment:1,015/1,015Sites: 310RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ2 2016ABP 980Breast CancerNCT01901146

Primary: Percentage of Participants With a Pathologic Complete Response (3 to 7 weeks after the last dose of study drug in the neoadjuvant phase)Enrollment:725/725Sites: 98RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ2 2016DenosumabCancer, Cataract, Low Bone Mineral DensityNCT00925600

Primary: Percentage of Participants With Lens Opacification Event Development or Progression by Month 12 (12 months)Enrollment:769/769Sites: 172RANDOMIZED, QUADRUPLE, SUPPORTIVE_CARE

Phase 2May 17, 2016intensive chemotherapy and hematopoietic stem cell rescuePrimary Central Nervous System LymphomaNCT00863460

Primary: 2-years progression-free survival in each arm (2 years after inclusion)Enrollment:140/140Sites: 23RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2016DenosumabSteroid-induced Osteopor, Glucocorticoid-induced OsteporNCT01575873

Primary: Percent Change From Baseline in Lumbar Spine Bone Mineral Density at Month 12 (Non-inferiority Analysis) (Baseline and month 12)Enrollment:795/795Sites: 99RANDOMIZED, TRIPLE, TREATMENT

Phase 3PositiveQ3 2016ErenumabMigraineNCT02483585

Primary: Change From Baseline in Monthly Migraine Days at Week 12 (4-week baseline phase and the last 4 weeks of the 12-week double-blind treatment phase)Enrollment:577/577Sites: 76RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2PositiveQ3 2016Talimogene laherparepvecMelanomaNCT01740297

Primary: Phase 1b: Number of Participants With Dose-limiting Toxicities (The DLT evaluation period was 6 weeks from the initial administration of ipilimumab (week 6 to 12).)Enrollment:217/217Sites: 40RANDOMIZED, TREATMENT

Phase 3PositiveQ4 2016EvolocumabDyslipidemiaNCT01764633

Phase 3Q1 2017CinacalcetSecondary Hyperparathyroidism, Chronic Kidney DiseaseNCT02341417

Primary: Number of Participants With Adverse Events (From first dose of study drug in the extension study up to 4 weeks after the last dose; 32 weeks.)Enrollment:28/28Sites: 33NA, TREATMENT

Phase 3Q1 2017interferon γ-1bFriedreich's AtaxiaNCT02797080

Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs (Baseline/Day 1 (Week 28 Follow-Up Visit for Study HZNP-ACT-302 ([NCT02593773]) through end of study; mean (SD) duration of treatment was 99.2 (58.48) days.)Enrollment:38/38Sites: 4NA, TREATMENT

Phase 3PositiveQ3 2017EvolocumabHypercholesterolemiaNCT02634580

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at the Mean of Weeks 10 and 12 (Baseline and Weeks 10 and 12)Enrollment:61/61Sites: 35RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3NegativeQ3 2017Breast CancerNCT01077154

Primary: Bone Metastasis-free Survival (BMFS) (From randomization until the primary analysis data cut-off date of 31 August 2017; median (minimum, maximum) time on study was 67.2 (0.0, 85.9) and 67.0 (0.0, 86.6) months in each treatment group respectively.)Enrollment:4,509/4,509Sites: 459RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3PositiveQ1 2018RomosozumabPostmenopausal OsteoporosisNCT02791516

Primary: Percent Change From Baseline to Month 6 in Bone Mineral Density at the Lumbar Spine (Baseline and month 6)Enrollment:67/67Sites: 10RANDOMIZED, TRIPLE, TREATMENT

Phase 2Jul 5, 2018carfilzomibSmoldering Multiple MyelomaNCT02415413

Primary: Efficacy- Number of Immunophenotypic complete remission rate (Flow-CR) at day +100 after induction and HDT-ASCT (4 months)Enrollment:Target 90Sites: 16NA, TREATMENT

Phase 3Q4 2018DexamethasoneRelapsed and Refractory Multiple MyelomaNCT03029234

Primary: Overall Response Rate (ORR) After at Least 6 Cycles of Treatment Assessed by the Independent Review Committee (Response was assessed every 28 days until disease progression; ORR was analyzed after all participants received at least 6 cycles or discontinued treatment; the data cut-off date was 5 November 2018; median follow-up time for progression was 8.9 months.)Enrollment:126/126Sites: 17NA, TREATMENT

Phase 2Q2 2019BlinatumomabHigh-risk Diffuse Large B-Cell LymphomaNCT03023878

Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events (From the start of first infusion of IP to 30 days after the end of last infusion of IP; median (min, max) treatment duration was 56 (16, 84) days)Enrollment:47/47Sites: 24NA, TREATMENT

Phase 2ApprovedQ2 2019Talimogene LaherparepvecCompletely Resectable Stage IIIB, IIIC, or IVM1a MelanomaNCT02211131

Primary: Recurrence-Free Survival (RFS) (24 months after last participant was randomized (data cutoff date of 30 April 2019))Enrollment:150/150Sites: 46RANDOMIZED, TREATMENT

Phase 2NegativeQ3 2019OprozomibMultiple MyelomaNCT01881789

Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) (Cycle 1, 28 days)Enrollment:22/22Sites: 14NON_RANDOMIZED, TREATMENT

Phase 2Q4 2019Consolidation with 4 cycles of CarCyDexMultiple MyelomaNCT02315716

Primary: Response rate (Within 4 weeks of the end of induction treatment)Enrollment:281/281Sites: 20RANDOMIZED, TREATMENT

Phase 2NegativeQ2 2020CCX140-BFocal Segmental GlomerulosclerosisNCT03703908

Phase 3PositiveQ4 2020EvolocumabCoronary Artery Disease (CAD)NCT03570697

Phase 3Q3 2021COVID-19NCT04590586

Primary: Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29 (Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29)Enrollment:515/515Sites: 59RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Jul 30, 2022CarfilzomibMultiple MyelomaNCT04430894

Primary: Complete Response (CR + Stringent CR) Rate (112 Days)Enrollment:50/50Sites: 3NON_RANDOMIZED, SINGLE, TREATMENT

Phase 3PositiveQ3 2022AMG 510KRAS p, G12c Mutated /Advanced Metastatic NSCLCNCT04303780

Primary: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months)Enrollment:345/345Sites: 274RANDOMIZED, TREATMENT

Phase 3Q4 2022ABP 215Metastatic Non-small Cell Lung Cancer (NSCLC), Non-squamous NSCLCNCT04466917

Primary: Objective response rate (ORR) (From Day 1 to Week 19 (EOS))0RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2022CarfilzomibRelapsed or Refractory Multiple MyelomaNCT04191616

Primary: Overall Response Rate (ORR) As Assessed by the Independent Review Committee (IRC) (From day 1 cycle 1 until the primary analysis (PA) data cutoff (DCO); the mean duration of KPd treatment as of the DCO was 42.0 weeks)Enrollment:54/54Sites: 46NA, TREATMENT

Phase 2Feb 7, 2023Talimogene LaherparepvecSoft Tissue SarcomaNCT04599062

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) (14 weeks)Enrollment:8/8Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Q2 2023VIB7734Lupus Erythematosus, SystemicNCT04925934

Primary: Number of Participants Achieving a BILAG-2004 Index-based Combined Lupus Assessment (BICLA) Response and an OGC Dose ≤ 7.5 mg/Day and ≤ Baseline Dose of Prednisone or Equivalent at Week 48 (Week 48)Enrollment:214/214Sites: 67RANDOMIZED, DOUBLE, TREATMENT

Phase 2Jun 28, 2023Carfilzomib, lenalidomide, dexamethasone (KRd) + DaratumumabMultiple MyelomaNCT04113018

Primary: Number of Participants With Complete Response or Stringent Complete Response to Induction (From enrollment to best response determined at the end of induction (8 28-day cycles); the median length of induction was 32 weeks)Enrollment:39/39Sites: 1NA, TREATMENT

Phase 2Q3 2023Rozibafusp AlfaSystemic Lupus Erythematosus (SLE)NCT04058028

Primary: Number of Participants With a SLE Responder Index (SRI-4) Response at Week 52 (Week 52)Enrollment:244/244Sites: 147RANDOMIZED, TREATMENT

Phase 2Sep 26, 2023CarfilzomibSmoldering Multiple MyelomaNCT03289299

Primary: Stringent complete response rate (During treatment)Enrollment:87/87Sites: 10NA, TREATMENT

Phase 2NegativeQ1 2024DaxdilimabLupus NephritisNCT05540665

Primary: Percentage of Participants Who Achieved CRR at Week 48 Through Week 52 (Week 48 to Week 52)Enrollment:19/19Sites: 52RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2024RomiplostimChemotherapy-induced ThrombocytopeniaNCT03362177

Phase 2Q1 2024CarfilzomibMultiple Myeloma, Smoldering Multiple MyelomaNCT03815279

Primary: Rate of MRD negativity (36 months after study enrollment)Enrollment:Target 80Sites: 1NON_RANDOMIZED, TREATMENT

Phase 2Feb 28, 2024BlinatumomabB-cell Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, B-Cell ALL, ChildhoodNCT04746209

Primary: Percentage of patients who are able to receive the blinatumomab infusion [Feasibility] (Day +100 post-HCT)Enrollment:Target 25Sites: 1NON_RANDOMIZED, TREATMENT

Phase 3PositiveQ2 2024InebilizumabIg G4 Related DiseaseNCT04540497

Primary: RCP: Time to Disease Flare (Up to Week 52)Enrollment:135/135Sites: 72RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q2 2024inebilizumabMyasthenia GravisNCT04524273

Primary: Change From Baseline at Week 26 in Myasthenia Gravis Activities of Daily Living (MG-ADL) Score in the Overall Study Population (Baseline and Week 26)Enrollment:238/238Sites: 104RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2NegativeQ3 2024HZN-825Idiopathic Pulmonary FibrosisNCT05032066

Phase 2Aug 1, 2024PanitumumabTreatment Related CancerNCT04034173

Primary: Overall Response Rate (up to 60 months)Enrollment:3/3Sites: 1RANDOMIZED, TREATMENT

Phase 3Sep 30, 2024IsatuximabMultiple MyelomaNCT04934475

Primary: Negative MRD rate (Time Frame: change from post induction baseline MRD at end of consolidation phase (6 months))Enrollment:791/791Sites: 73RANDOMIZED, TREATMENT

Phase 3Q1 2025TarlatamabSmall Cell Lung Cancer (SCLC)NCT05740566

Primary: Overall Survival (OS) (From randomization up to minimum of death or primary completion DCO date 29 January 2025; median (min, max) time on the study was 8.6 (0.1, 18.5) months)Enrollment:509/509Sites: 223RANDOMIZED, TREATMENT

Phase 2Q1 2025TarlatamabExtensive Stage Small Cell Lung CancerNCT06502977

Primary: Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) (From first dose of trial drug up to a minimum of last dose + 65 days or data cutoff date; median (min, max) time on trial was 3.4 (2.2, 6.5) months at data cut off)Enrollment:32/32Sites: 12NA, TREATMENT

Phase 2Apr 15, 2025IsatuximabMultiple Myeloma in Relapse, Multiple Myeloma, RefractoryNCT04287855

Primary: Efficacy of trial treatment (Up to 5 years)Enrollment:82/82Sites: 1NA, TREATMENT

Phase 3Q2 2025BemarituzumabGastric Cancer, Gastroesophageal Junction AdenocarcinomaNCT05052801

Phase 2Jun 20, 2025Talimogene LaherparepvecSoft Tissue Sarcoma, Sarcoma, Soft TissueNCT06660810

Primary: pCR rate defined as the proportion of subjects with pathologic necrosis ≥ 90% (Weeks 12-14)Enrollment:2/2Sites: 1NA, TREATMENT

Phase 2Jun 24, 2025CarfilzomibPlasma Cell MyelomaNCT03756896

Primary: ≥ Complete response (CR) rates (Up to 2 years after study start)Enrollment:29/29Sites: 1NA, TREATMENT

Phase 3Jun 28, 2025FOLFOX regimenColorectal CancerNCT03635021

Primary: Progression-free survival rate at 35 months (35 months after date of randomization)Enrollment:Target 419Sites: 1RANDOMIZED, TREATMENT

Phase 3Q3 2025SotorasibColorectal Cancer (CRC)NCT05198934

Phase 2Jul 22, 2025Talimogene Laherparepvec (T-VEC)Sarcoma, Epithelioid Sarcoma, Cutaneous AngiosarcomaNCT03069378

Primary: Best Objective Response Rate (24 weeks)Enrollment:41/41Sites: 5NA, TREATMENT

Phase 3Q3 2025EvolocumabCoronary Heart Disease (CHD)NCT03872401

Phase 3Jul 31, 2025Carfilzomib Lenalidomide DexamethasoneMultiple MyelomaNCT04483739

Primary: Rate of MRD negativity after ASCT consolidation treatment by NGS (The end of consolidation, average of 12 months)Enrollment:302/302Sites: 41RANDOMIZED, TREATMENT

Phase 2Aug 7, 2025RegorafenibColorectal CancerNCT04787341

Primary: Overall survival (30 months)Enrollment:213/213Sites: 1RANDOMIZED, TREATMENT

Phase 2Q4 2025Maridebart CafraglutideType 2 Diabetes Mellitus (T2DM)NCT06660173

Primary: Change From Baseline to Week 24 in Hemoglobin A1c (HbA1c) (Baseline to Week 24)Enrollment:409/409Sites: 96RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q4 2025BemarituzumabGastric Cancer, Gastroesophageal Junction AdenocarcinomaNCT05111626

Phase 3Q4 2025Erenumab Dose 1MigraineNCT03836040

Primary: Change from baseline in MMDs (Baseline through week 12 of the double blind treatment phase)Enrollment:457/457Sites: 119RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q4 2025ApremilastPlaque PsoriasisNCT05565560

Primary: Achievement of a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least 2 points reduction from baseline at Week 16 (Week 16)Enrollment:17/17Sites: 29NA, TREATMENT

Phase 2Q4 2025BemarituzumabGastric Cancer, Gastroesophageal Junction CancerNCT05322577

Phase 2Q1 2026BlinatumomabB Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic LeukemiaNCT06054113

Primary: Number of Participants with Complete Remission (CR) (Up to 84 days)Enrollment:18/18Sites: 7NA, TREATMENT

Phase 3Q1 2026TeprotumumabThyroid Eye DiseaseNCT06248619

Primary: Proptosis responder rate (percentage of participants with a ≥ 2-mm reduction from baseline in proptosis in the study eye without deterioration [≥ 2-mm increase] of proptosis in the fellow eye). (Week 24)Enrollment:89/89Sites: 38RANDOMIZED, TRIPLE, TREATMENT

Phase 2Q1 2026AnvumetostatMTAP-null Non-Small-Cell Lung Cancer, MTAP-null Solid TumorsNCT05975073

Phase 2Q1 2026HZN-1116Sjogren's SyndromeNCT06312020

Phase 2Q1 2026BlinatumomabAcute Lymphoblastic Leukemia, Philadelphia Chromosome-PositiveNCT04329325

Primary: Proportion of evaluable patients achieving complete molecular response (7 months)Enrollment:17/17Sites: 2NA, TREATMENT

Phase 3Q2 2026RocatinlimabPrurigo NodularisNCT06527404

Phase 2Q2 2026RocatinlimabAsthmaNCT06376045

Primary: Annualized Rate of Composite Endpoint for Exacerbations (CompEx) Events During the Blinded Treatment Period (Up to Week 48)Enrollment:317/317Sites: 154RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2026RomiplostimChemotherapy-induced ThrombocytopeniaNCT03937154

Primary: Incidence of either a chemotherapy dose delay or reduction (48 days)Enrollment:145/145Sites: 139RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q2 2026AnvumetostatAdvanced MTAP-null Solid TumorsNCT05094336

Primary: Parts 1 and 2: Number of Participants Who Experience a Dose-Limiting Toxicity (DLT) (28 days)Enrollment:329/329Sites: 75NON_RANDOMIZED, TREATMENT

Phase 2Q2 2026sotorasibKRAS p.G12C Mutant Advanced Solid TumorsNCT03600883

Phase 3Q2 2026RocatinlimabAtopic DermatitisNCT05882877

Phase 2Q2 2026avutometinib and sotorasibNon Small Cell Lung Cancer, KRAS Activating MutationNCT05074810

Primary: Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinib (From start of treatment to confirmation of RP2D; 28 days)Enrollment:Target 153Sites: 35NON_RANDOMIZED, TREATMENT

Phase 2Q2 2026DaratumumabMyeloma, Multiple MyelomaNCT03500445

Primary: Rate of stringent complete response (sCR) (8 months)Enrollment:Target 75Sites: 1NA, TREATMENT

Phase 2Jun 30, 2026Blinatumomab 9ugAcute Lymphoblastic Leukemia, B-cell Non Hodgkin Lymphoma, Pre B-Cell Acute Lymphoblastic LeukaemiaNCT03114865

Primary: Overall survival at two years post first treatment cycle (2 years)Enrollment:44/44Sites: 1NA, TREATMENT

Phase 3Jul 14, 2026TezepelumabEosinophilic EsophagitisNCT05583227

Primary: Histologic response of peak esophageal eosinophil per HPF count of ≤ 6 across all available esophageal levels (Week 24)Enrollment:368/368Sites: 124RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q3 2026ApremilastPlaque PsoriasisNCT06088199

Phase 3Q3 2026DazodalibepSjogren's SyndromeNCT06104124

Primary: Change from baseline in European Alliance of Associations for Rheumatology Sjögren's Syndrome Disease Activity Index (ESSDAI) Score (At Week 48)Enrollment:651/651Sites: 206RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Sep 30, 2026PrednisoneAcute Lymphoblastic Leukemia, Acute Lymphoblastic LymphomaNCT03117751

Primary: Event-free survival of ALL patients (EFS) (At 3.5 years after enrollment of the last participant)Enrollment:790/790Sites: 8RANDOMIZED, SINGLE, TREATMENT

Phase 3Q4 2026DazodalibepSjögren's Syndrome (SS)NCT06245408

Primary: Change from baseline in ESSPRI score (At Week 48)Enrollment:434/434Sites: 194RANDOMIZED, QUADRUPLE, TREATMENT

Phase 2Q4 2026anvumetostatMTAP-deleted NSCLCNCT06593522

Primary: Objective Response (OR) per RECIST 1.1 (Up to 35 months)Enrollment:61/61Sites: 91RANDOMIZED, TREATMENT

Phase 3Q4 2026ABP 234Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)NCT06430866

Primary: Area Under the Serum Concentration-time Curve (AUC) From Time 0 to 21 Days (AUC21d) Following the First Dose (21 days)Enrollment:163/163Sites: 128RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q4 2026RomiplostimLymphoma Patients, ThrombocytopeniaNCT04673266

Primary: measure of incidence of indication for dose delays (1 year)Enrollment:11/11Sites: 7NA, TREATMENT

Phase 2Q1 2027AMG 732Thyroid Eye DiseaseNCT06401044

Primary: Part A: Number of Participants With Treatment-emergent Adverse Events (Day 1 through Week 36 (End of Study))Enrollment:94/94Sites: 44RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2027Maridebart cafraglutideType 2 Diabetes Mellitus (T2DM), Obesity, OverweightNCT06858878

Primary: Percent Change from Baseline in Body Weight at Week 72 (Baseline and Week 72)Enrollment:1,105/1,105Sites: 187RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q1 2027Maridebart CafraglutideObesityNCT06858839

Primary: Percent Change From Baseline in Body Weight at Week 72 (Baseline and Week 72)Enrollment:3,853/3,853Sites: 243RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2027Trastuzumab + PaclitaxelHER2-positive Breast Cancer, Operable Breast CancerNCT03571633

Primary: Pathological complete response rate (pCR) (16 weeks after start of treatment)Enrollment:Target 90Sites: 9RANDOMIZED, TREATMENT

Phase 2Feb 1, 2027BortezomibMultiple MyelomaNCT04268498

Primary: Rate of Minimal Residual Disease (MRD) Negativity (Up to 32 weeks)Enrollment:310/310Sites: 7RANDOMIZED, TREATMENT

Phase 2Mar 2, 2027RomosozumabOsteoporosis, Post-menopausalNCT06973109

Primary: Change in Hounsfield Units (HU) at L1 Vertebra (Baseline, 3 months post-op, and 9 months post-op)0Sites: 1RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q1 2027Romosozumab Prefilled Syringe [Evenity]Premenopausal Idiopathic OsteoporosisNCT04800367

Primary: Percent change in lumbar spine BMD by DXA (Baseline-12 months)Enrollment:30/30Sites: 1NA, TREATMENT

Phase 2Q2 2027InebilizumabNeuromyelitis Optica Spectrum DisorderNCT05549258

Primary: Maximum Observed Concentration (Cmax) of Inebilizumab (Day 1 to Week 28)Enrollment:Target 15Sites: 19NA, TREATMENT

Phase 2Apr 15, 2027TarlatamabMetastatic/Locally Advanced Small-Cell Lung Cancer, Metastatic/Locally Advanced Poorly Differentiated NEC, Metastatic/Locally Advanced High-grade MTCNCT07016230

Primary: To estimate the objective response rate (ORR) (Within the 4 months of treatment initiation)Enrollment:Target 40Sites: 3NON_RANDOMIZED, TREATMENT

Phase 3Q2 2027Ocrelizumab (US)Relapsing-remitting Multiple Sclerosis (RRMS)NCT06700343

Primary: Area Under the Serum Concentration-time Curve (AUC) From Time 0 to Day15 (AUC0-d15) Following Infusion 1 ofthe Initial Dose of InvestigationalProduct (IP) (Day 1 to Day 15)Enrollment:152/152Sites: 109RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2027Maridebart cafraglutideObesity DiseaseNCT06987695

Primary: Percent Change From Baseline in Body Weight at Week 72 (Baseline and Week 72)Enrollment:279/279Sites: 30RANDOMIZED, DOUBLE, TREATMENT

Phase 2Q2 2027DaratumumabMultiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in RelapseNCT04176718

Phase 3Q2 2027RomosozumabOsteogenesis ImperfectaNCT05972551

Phase 3Q2 2027EtelcalcetideSecondary HyperparathyroidismNCT03969329

Primary: Percent Change From Baseline in iPTH at Weeks 20 to 26 (Week 20 to 26)Enrollment:Target 24Sites: 23NA, TREATMENT

Phase 3Q2 2027SotorasibNon-Small Cell Lung Cancer (NSCLC)NCT05920356

Phase 3Q3 2027TarlatamabExtensive-Stage Small-Cell Lung Cancer, Small-Cell Lung CancerNCT06211036

Phase 3Q3 2027AvacopanVasculitisNCT06321601

Phase 2Q3 2027Maridebart cafraglutideOverweight or Obesity and Elevated Liver FatNCT07441252

Phase 2Aug 31, 2027TarlatamabMetastatic Prostate CancerNCT07111507

Phase 3Q3 2027TarlatamabSmall Cell Lung CancerNCT07778316

Phase 3Q3 2027Maridebart cafraglutideObesity, Obstructive Sleep ApneaNCT07225686

Phase 3Q3 2027Maridebart cafraglutideObstructive Sleep ApneaNCT07226765

Phase 3Q3 2027BlinatumomabAcute Lymphoblastic Leukemia, Mixed Phenotype Acute LeukemiaNCT05327894

Phase 2Q3 2027bemarituzumab, paclitaxel, ramucirumabMetastatic Gastro-esophageal AdenocarcinomaNCT06680622

Primary: Objective response rate (ORR) (from date of enrollment to date of last response acc. to RECIST v1.1 or death due to any cause, through study completion, up to 33 months)Enrollment:Target 126Sites: 35NON_RANDOMIZED, TREATMENT

Phase 2Q3 2027PanitumumabCancer, Tumors, NeoplasmNCT02925234

Phase 2Oct 20, 2027AMG 510Lung CancerNCT05118854

Phase 2Oct 31, 2027CarboplatinBreast Carcinoma, Breast Lump, EdemaNCT02876107

Phase 2Oct 31, 2027Interferon gamma-1bAcute Myeloid Leukemia, Myelodysplastic SyndromesNCT06529731

Phase 2Q4 2027BlinatumomabB Cell Precursor Acute Lymphoblastic LeukemiaNCT04521231

Phase 2Nov 30, 2027BlinatumomabAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein ExpressionNCT03263572

Phase 3Q4 2027Maridebart cafraglutideObesity, OverweightNCT07684235

Phase 3Q4 2027Maridebart CafraglutideObesity, Overweight, Diabetes Mellitus, Type 2NCT07684144

Phase 2Q4 2027TarlatamabRelapsed/Refractory Small Cell Lung CancerNCT05060016

Primary: Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator (Up to a maximum of 61 months)Enrollment:222/222Sites: 80RANDOMIZED, TREATMENT

Phase 2Dec 31, 2027Treatment with blinatumomab given subcutaneously.Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), BCR-ABL Positive Acute Lymphoblastic LeukemiaNCT07301424

Phase 2Dec 31, 2027TarlatamabExtrapulmonary Small Cell Carcinoma and Neuroendocrine CarcinomaNCT06816394

Phase 2Dec 31, 2027TarlatamabExtensive Stage Lung Small Cell CarcinomaNCT07423585

Phase 3Q1 2028Maridebart CafraglutideObesity or OverweightNCT07575399

Phase 3Q1 2028ABP 234Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerNCT06311721

Phase 3Q1 2028ABP 206MelanomaNCT06054555

Phase 2Q1 2028AMG 732Thyroid Eye DiseaseNCT07438405

Phase 2Mar 3, 2028TarlatamabAstrocytic Tumor, Oligodendroglial TumorNCT06776250

Phase 3Q1 2028ApremilastActive Juvenile Psoriatic ArthritisNCT04804553

Primary: Number of Participants who Achieve American College of Rheumatology Pediatric (ACR) Pedi 30 Response at Week 16 (Baseline to Week 16)Enrollment:Target 60Sites: 45RANDOMIZED, QUADRUPLE, TREATMENT

Phase 3Q1 2028Atherosclerotic Cardiovascular DiseaseNCT05581303

Phase 3Q2 2028Osteogenesis ImperfectaNCT07366086

Phase 2Apr 24, 2028Tarlatamab treatmentDLL3-expressing Tumors, Advanced TumorsNCT06788938

Phase 2Q2 2028DexamethasoneAcute Lymphoblastic Leukemia, Lymphoblastic LymphomaNCT06533748

Phase 3May 31, 2028TezepelumabAsthmaNCT06023589

Phase 3Q2 2028OlpasiranCardiovascular DiseaseNCT07293260

Phase 3Q2 2028PegloticaseUncontrolled GoutNCT07388498

Primary: Number of Participants Achieving Month 6 Response at Weeks 20, 21, 22, 23, and 24 (Month 6 (Weeks 20, 21, 22, 23, and 24))Enrollment:Target 270Sites: 71RANDOMIZED, DOUBLE, TREATMENT

Phase 3Q2 2028Maridebart CafraglutideAtherosclerotic Cardiovascular Disease, Overweight, ObesityNCT07037433

Phase 3Q2 2028Maridebart cafraglutideHeart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, ObesityNCT07037459

Phase 2Q3 2028SotorasibAdvanced Solid TumorsNCT07172919

Phase 2Jul 1, 2028Belantamab mafodotinMultiple Myeloma, Relapse Multiple MyelomaNCT05789303

Phase 2Q3 2028InebilizumabSystemic Lupus Erythematosus, Active Refractory Rheumatoid ArthritisNCT06570798

Phase 2Q3 2028Carfilzomib + IbrutinibWaldenstrom MacroglobulinemiaNCT04263480

Phase 3Q3 2028FOLFIRI RegimenMetastatic Colorectal CancerNCT06252649

Phase 2Q4 2028BlinatumomabRelapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic LeukemiaNCT07134088

Primary: Phase 1b: Number of Participants who Experienced Dose Limiting Toxicities (DLTs) (Up to 29 days)Enrollment:Target 104Sites: 5NON_RANDOMIZED, TREATMENT

Phase 2Q4 2028DexamethasoneLymphoblastic LeukemiaNCT05848687

Phase 2Q4 2028TarlatamabAdvanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary OriginNCT07061080

Phase 3Q1 2029XaluritamigMetastatic Castration-resistant Prostate CancerNCT06691984

Phase 3Q1 2029TarlatamabSmall-cell Lung Cancer, Extensive Stage Small-cell Lung CancerNCT07005128

Phase 2Q1 2029Blinatumomab InjectionB-cell Acute Lymphoblastic Leukemia, B-Cell Acute Lymphoblastic Leukemia, Adult, B-ALLNCT07313852

Phase 3Q1 2029EtelcalcetideSecondary Hyperparathyroidism, Chronic Kidney DiseaseNCT03633708

Phase 3Mar 13, 2029TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT06883305

Phase 3Mar 13, 2029TezepelumabChronic Obstructive Pulmonary Disease (COPD)NCT06878261

Phase 2Q2 2029Carfilzomib, Lenalidomide, Dexamethasone, Belantamab MafodotinMultiple MyelomaNCT04822337

Primary: Establish Maximum Tolerated Dose (MTD) (time to complete Cycle 1 (28 days))Enrollment:Target 70Sites: 2NON_RANDOMIZED, TREATMENT

Phase 2Q2 2029TarlatamabSmall Cell Lung Cancer (SCLC)NCT06745323

Phase 2Q3 2029Subcutaneous BlinatumomabCD19 Positive, Mixed Phenotype Acute Leukemia (MPAL)NCT07222579

Phase 3Q3 2029BlinatumomabNewly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)NCT04994717

Phase 3Q3 2029RomiplostimPrimary Immune ThrombocytopeniaNCT07700238

Phase 2Q4 2029TarlatamabExtensive Stage Lung Small Cell CancerNCT07203053

Phase 2Q4 2029TarlatamabGlioma, CNS Tumor, Adult, CNS Tumor, ChildhoodNCT07243470

Phase 3Q4 2029DazodalibepSjögren's SyndromeNCT06747949

Phase 3Q1 2030XaluritamigMetastatic Castration-resistant Prostate CancerNCT07213674

Phase 3Q1 2030ApremilastBehçet DiseaseNCT04528082

Phase 2Q1 2030InebilizumabGeneralized Myasthenia GravisNCT06987539

Phase 3Q2 2030TarlatamabLimited Stage Small Cell Lung Cancer, Small Cell Lung CancerNCT06117774

Phase 2Q2 2030TarlatamabMelanoma, Medullary Thyroid Cancer, Sinonasal Undifferentiated CarcinomaNCT06814496

Phase 3Q3 2030AvacopanGranulomatosis With Polyangiitis, Wegener's, GPANCT07176546

Phase 2Oct 12, 2030BlinatumomabPhase 2 Study, Blinatumomab, Acute Lymphoblastic LeukemiaNCT07192237

Phase 2Q2 2031InebilizumabImmunoglobulin G4-related DiseaseNCT07222553

Phase 3Q3 2031InebilizumabAutoimmune Hepatitis, AIHNCT07598825

Phase 3Q3 2031InebilizumabGlomerulonephritis, MembranousNCT07851220

Phase 2Sep 30, 2031BlinatumomabPhase II Clinical Trial, Blinatumomab, OlverembatinibNCT07178912

Phase 2Sep 30, 2031BlinatumomabB-cell Acute Lymphoblastic LeukemiaNCT07153796

Phase 3Q4 2031OlpasiranCardiovascular DiseaseNCT07136012

Phase 3Q4 2031BlinatumomabPhiladelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic LeukemiaNCT07223190

Phase 3Q2 2033Omitted DoxorubicinLeukemia, Acute LymphoblasticNCT04307576

Phase 3Q1 2036ApremilastBehçet's Disease, Juvenile Psoriatic ArthritisNCT05767047

Phase 2TBDFilgrastimHIV Infections, CytopeniasNCT00002126

Enrollment:Target 250Sites: 22TREATMENT

Phase 2TBDDarbepoetin alfaAnemia, Non-Myeloid Malignancies, CancerNCT00111462

Primary: Achieving a hemoglobin concentration greater than or equal to 12.0 g/dL or a greater than or equal to 2.0-g/dL increase in hemoglobin concentration compared to baselineRANDOMIZED, TREATMENT

Phase 2TBDpegfilgrastimBreast CancerNCT00124111

Phase 2NegativeTBDAMG 114Anemia, CancerNCT00119600

Primary: Incidence and severity of adverse eventsRANDOMIZED, DOUBLE, TREATMENT

Phase 2TBDABX-EGFNon-Small Cell Lung Cancer, Neoplasm Metastasis, Lung CancerNCT00034346

Primary: Time to Disease ProgressionEnrollment:Target 194RANDOMIZED, TREATMENT

Phase 2TBDABX-EGF (panitumumab)Metastatic Colorectal CancerNCT00327119

Enrollment:Target 50NON_RANDOMIZED, TREATMENT

Amgen Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Position Trend

Short Interest

Catalysts

Conferences

Recent News & Research

Position Details

Know which insider moves are real

Also Held by These Funds

Research Links

Related Research